Wegovy vs Mounjaro: Complete Dose Range Comparison
Is Mounjaro or Wegovy Better for Complete Dose Availability?
When considering whether Mounjaro or Wegovy is better suited to your needs, dose availability plays a crucial role in treatment continuity. EverydayMeds stocks every Wegovy dose from 0.25mg starter through to 2.4mg maintenance, ensuring seamless progression without pharmacy switching. The complete escalation pathway—0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance—is available with next-day delivery once prescribed. This comprehensive range means you can begin and maintain your entire Wegovy journey with one trusted pharmacy.
Both Mounjaro and Wegovy require dose escalation, but their mechanisms differ significantly. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones, while Mounjaro contains tirzepatide, which targets both GIP and GLP-1 receptors as a dual agonist. Your prescriber can determine which mechanism may be more suitable based on your individual health profile and treatment goals, with both options available through EverydayMeds' clinical assessment process.
Wegovy Pricing and Value Across All Doses
Understanding the cost implications when comparing Mounjaro versus Wegovy helps inform your treatment decision. EverydayMeds offers transparent Wegovy pricing: 0.25mg starter dose £79.99, 0.5mg £94.99, 1mg £99.99, 1.7mg £139.99, and 2.4mg maintenance £209.99. New customers apply code FIRST40 at checkout, while returning customers use DOSE25 to access these prices. Bundle options like the Intro Duo (0.25mg & 0.5mg) at £169.99 provide convenient packaging for your first two months of treatment.
Long-term value becomes important when considering maintenance therapy, as weight management is typically an ongoing commitment. The Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, offering treatment continuity without frequent reordering. This comprehensive pricing structure allows you to plan your treatment journey financially, whether you're starting with the 0.25mg dose or transitioning to maintenance therapy with confidence in supply availability.
Clinical Evidence: Mounjaro vs Wegovy Research
When evaluating whether Mounjaro or Wegovy is better supported by clinical evidence, both demonstrate significant efficacy in their respective trials. Wegovy's STEP programme showed substantial results, with STEP 1 demonstrating approximately 15% average weight loss at 68 weeks versus 2.4% with placebo, when used alongside a reduced-calorie diet and increased physical activity. The SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events, highlighting Wegovy's broader health benefits beyond weight management.
Mounjaro's SURMOUNT trials demonstrated the effectiveness of the dual GIP and GLP-1 receptor approach, though direct head-to-head comparisons between the medications aren't available due to different trial designs and populations. Both prescription-only medicines require clinical assessment and ongoing medical supervision, with your prescriber best positioned to evaluate which mechanism—single or dual incretin receptor targeting—aligns with your individual treatment needs and health profile.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy's active ingredient, semaglutide, functions as a GLP-1 receptor agonist that mimics the action of naturally occurring incretin hormones in your body. When you eat, these hormones signal fullness to your brain and slow gastric emptying, helping you feel satisfied with smaller portions. Wegovy enhances this natural process by binding to GLP-1 receptors in areas of the brain that regulate appetite and food intake, potentially reducing cravings and promoting earlier satiety signals. The once-weekly FlexTouch pen delivers a consistent dose that maintains therapeutic levels throughout the week, supporting sustained appetite regulation. This mechanism works optimally when combined with a reduced-calorie diet and increased physical activity as part of a comprehensive weight management approach supervised by healthcare professionals.
Wegovy Ordering Process: Assessment to Delivery
Accessing Wegovy through EverydayMeds begins with a comprehensive 3-minute online clinical assessment that evaluates your suitability for this prescription-only medicine. Our qualified prescribers review your medical history, current medications, and weight management goals within 3 working days (or 24 hours with express service) to ensure safe and appropriate prescribing. Once approved, your chosen dose ships via next-day delivery using cold-chain temperature-controlled packaging to maintain medication integrity from our GPhC-registered pharmacy (#9012878) directly to your door. The process includes detailed injection guidance and ongoing support throughout your treatment journey. Payment options accommodate single pens or convenient bundles, with discount codes applied at checkout to ensure transparent pricing for your chosen Wegovy dose.
Storage and Practical Considerations in Wegovy vs Mounjaro
Storage requirements represent a key practical difference when determining whether Mounjaro or Wegovy better suits your lifestyle needs. Wegovy pens maintain potency for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limit, making Wegovy more convenient for travel or temporary storage flexibility. Prior to first use, both medications require refrigeration at 2-8°C, but Wegovy's extended room temperature stability provides greater peace of mind for business trips or holidays. The FlexTouch pen design offers user-friendly injection with clear dose confirmation, while the mandatory dose escalation schedule—starting at 0.25mg and increasing every four weeks—applies to both medications to minimise potential gastrointestinal side effects and optimise tolerability throughout your treatment journey.
Complete Dose Journey: Why All Doses Matter for Treatment Success
The availability of every Wegovy dose becomes critical when comparing Mounjaro versus Wegovy for long-term treatment adherence and success. Missing doses during escalation can compromise treatment effectiveness and require restarting at lower doses, making pharmacy reliability essential for optimal outcomes. EverydayMeds' comprehensive stock ensures you never face treatment interruptions due to dose unavailability, whether you're beginning with 0.25mg or maintaining on 2.4mg. This continuity proves particularly valuable during the 16-week escalation period, where consistent progression supports tolerability and therapeutic benefit development.
The psychological benefit of knowing your maintenance dose will always be available cannot be understated in long-term weight management planning. Many patients report anxiety about pharmacy switching or dose availability affecting their progress, concerns eliminated by EverydayMeds' commitment to stocking the complete Wegovy range. Whether your prescriber recommends slower escalation, maintenance at a lower effective dose, or standard progression to 2.4mg, having assured access to every option through one trusted pharmacy provider supports treatment confidence and long-term success planning.
Start Your Wegovy Journey Today
Both Wegovy and Mounjaro are available from EverydayMeds, with your prescriber best positioned to determine which option aligns with your individual health profile and treatment goals. New customers can begin their Wegovy assessment today using code FIRST40 for starter dose access at £79.99, while returning customers apply DOSE25 for continued treatment. Our clinical team provides ongoing support throughout your dose escalation and maintenance journey, ensuring optimal outcomes with this prescription-only medicine. Visit our Wegovy collection at https://everydaymeds.co.uk/collections/wegovy to begin your assessment and secure your complete dose supply from our GPhC-registered pharmacy. Take the first step towards comprehensive weight management support with the confidence of complete dose availability and expert clinical guidance from EverydayMeds.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
